Cargando…

EHMTI-0105. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine

Detalles Bibliográficos
Autores principales:	Cernuda-Morollón, E, Martínez-Camblor, P, Serrano-Pertierra, E, Larrosa, D, Ramón, C, Pascual, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181987/ http://dx.doi.org/10.1186/1129-2377-15-S1-E24

Ejemplares similares

EHMTI-0104. VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine
por: Cernuda-Morollón, E, et al.
Publicado: (2014)

Increased levels of CGRP in peripheral blood in women with chronic migraine: A reliable biological marker
por: Cernuda-Morollon, E, et al.
Publicado: (2013)

EHMTI-0283. Predictors of early response to onabotulinumtoxin type a in chronic migraine
por: Mas-Sala, N, et al.
Publicado: (2014)

EHMTI-0270. Experience with onabotulinumtoxin type a in high-frequency episodic migraine
por: Pozo-Rosich, P, et al.
Publicado: (2014)

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
por: Goadsby, P, et al.
Publicado: (2014)

EHMTI-0326. OnabotulinumtoxinA for the treatment of chronic paroxysmal hemicrania: a case report
por: Dolezil, D
Publicado: (2014)

EHMTI-0146. Topiramate in migraine prevention
por: Ristic, S, et al.
Publicado: (2014)

From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment
por: Tanaka, Masaru, et al.
Publicado: (2023)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

EHMTI-0374. Gene-based pleiotropy across migraine with and migraine without aura
por: Nyholt, D, et al.
Publicado: (2014)

EHMTI-0239. Effect of chronic paracetamol treatment on the csd-induced cgrp expression in the trigeminal ganglion
por: Yisarakun, W, et al.
Publicado: (2014)

EHMTI-0111. Intra-variability of migraine attacks features
por: Viana, M, et al.
Publicado: (2014)

EHMTI-0086. Pure mestrual vestibular migraine
por: Mostardini, C, et al.
Publicado: (2014)

EHMTI-0049. Headache, migraine and epileptic seizures
por: Gligic, N, et al.
Publicado: (2014)

EHMTI-0089. Relationship of sleep bruxism and migraine
por: Kato, M, et al.
Publicado: (2014)

EHMTI-0018. CGRP receptor antagonists attenuate pain behavior induced by cortical spreading depression in freely moving rats
por: Filiz, A, et al.
Publicado: (2014)

EHMTI-0194. The impact of dizziness in tertiary care migraine patients
por: Sugrue, J, et al.
Publicado: (2014)

CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA
por: Moreno-Mayordomo, R., et al.
Publicado: (2019)

EHMTI-0199. CGRP modulates trigeminal ganglionic neuronal excitability in minimally low pH condition
por: Jansri, U, et al.
Publicado: (2014)

EHMTI-0055. Abnormal thalamic function in patients with vestibular migraine
por: Russo, A, et al.
Publicado: (2014)

EHMTI-0122. Serum micrornas as potential biomarkers of migraine
por: Andersen, HH, et al.
Publicado: (2014)

EHMTI-0107. Treatment of migraine in Croatia, year 2013
por: Cvetkovic, V Vukovic, et al.
Publicado: (2014)

EHMTI-0358. Improved chronic migraine after DTMS
por: Scatena, P, et al.
Publicado: (2014)

EHMTI-0348. Refractive errors in patients with migraine headache
por: Gunes, A, et al.
Publicado: (2014)

EHMTI-0050. Systemic and cerebral endothelial function in migraine
por: Zaletel, M, et al.
Publicado: (2014)

EHMTI-0189. Tryptophan-kynurenine metabolism in migraine patients
por: Majláth, Z, et al.
Publicado: (2014)

EHMTI-0070. Effect of occlusal sprint in migraine patients
por: Takeuchi, M, et al.
Publicado: (2014)

EHMTI-0230. Characteristics of menstrual and nonmenstrual migraine attacks in women with menstrual migraine
por: Vetvik, KG, et al.
Publicado: (2014)

EHMTI-0369. Migraine is a dysfunction of the mind – in networks creating reality
por: Hougaard, K, et al.
Publicado: (2014)

EHMTI-0380. The association of migraine susceptibility loci with severe migraine characteristics in a clinic-based migraine sample
por: Esserlind, A, et al.
Publicado: (2014)

EHMTI-0068. Facial plastic surgery for migraine therapy: personal procedures
por: Caruana, G, et al.
Publicado: (2014)

EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor
por: Xu, C, et al.
Publicado: (2014)

EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union
por: Matharu, M, et al.
Publicado: (2014)

EHMTI-0370. The performance of the ID-Migraine questionnaire in a Hungarian sample
por: Csepany, E, et al.
Publicado: (2014)

EHMTI-0249. Headache attributed to hypertension in chronic migraine patients
por: Grosu, O, et al.
Publicado: (2014)

EHMTI-0080. How migraine is affected by therapies for multiple sclerosis
por: Condello, C, et al.
Publicado: (2014)

EHMTI-0030. Migraine pain location in adult: the bangladeshi experience
por: Haque, R
Publicado: (2014)

EHMTI-0044. Variability of clinical features in attacks of migraine with aura
por: Hansen, J Møller, et al.
Publicado: (2014)

EHMTI-0037. Botulinum A toxin for treatment of chronic migraine
por: Grazzi, L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6lpr5r8qig6hda9vk6habvsm4m